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Abstract
Introduction: While microvascular disease is well described in systemic sclerosis (SSc), it is still unclear whether the
occurrence of ischemic macrovascular events and atherosclerosis is enhanced among patients with SSc.
Methods: In this study, 111 SSc patients (74% of prevalent cases in Stockholm County) and 105 age- and sex-
comparable population controls were investigated. Previous ischemic arterial events were tabulated. As surrogate
measures of atherosclerosis, plaque occurrence and intima-media thickness (IMT) were determined with carotid
ultrasound and the ankle-brachial index (ABI) was calculated. Traditional cardiovascular risk factors were recorded
and we also measured biomarkers indicating systemic inflammation and endothelial activation/dysfunction.
Results: Mean age was 62 ± 12 years for patients and controls. Ischemic arterial events were more common, due
to increased occurrence of ischemic heart disease (IHD) and ischemic peripheral vascular disease (IPVD), in the
patient group (12% vs. 4%, P = 0.03 and 9% vs. 0%, P = 0.003 respectively). On a group level, there was no
difference regarding the occurrence of ischemic cerebrovascular disease, the frequency of plaques, IMT or ABI
between SSc patients and controls. Subgroup analyses revealed that patients with anticentromere antibodies (ACA
+) had more plaques and more ischemic arterial events compared to other SSc patients (67% vs. 39% and 32% vs.
11%; P = 0.006 and P = 0.01, respectively) and compared to controls (67% vs. 41% and 32% vs. 7%, P = 0.02 and P
= 0.0003, respectively). Biomarkers of inflammation/endothelial activation were generally increased among SSc
patients.
Conclusions: Patients with SSc are at enhanced risk for IHD and IPVD. The ACA+ SSc subgroup was particularly
affected with both ischemic arterial events and premature atherosclerosis. The microvascular vulnerability of ACA+
patients is previously well documented. We demonstrate that ACA+ SSc patients have an enhanced risk of
macrovascular injury as well. This group should be followed closely and modifiable cardiovascular risk factors
should be treated at an early stage.
Introduction
Systemic sclerosis (SSc) is an autoimmune rheumatic
disease characterized by fibrosis of the skin, microvascu-
lopathy and involvement of internal organs. Patients
with SSc have a shortened lifespan mainly due to heart
and lung manifestations [1]. In other autoimmune dis-
eases such as systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA) the occurrence of premature
cardiovascular morbidity and subclinical atherosclerosis
has been well documented [2,3]. Whether ischemic
macrovascular disease and/or accelerated atherosclerosis
also are features of SSc is unclear. Most previous studies
are fairly small and results contradictive [4-6], however,
a recent meta-analysis concluded that carotid intima-
media thickness (IMT) was greater in SSc patients than
in controls [7].
The pathogenesis of SSc is unknown, but activation of
B cells results in the production of antinuclear antibodies
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(ANA) in 90% of patients. The ANA specificities most
commonly demonstrated in SSc; anticentromere (ACA)
and antitopoisomerase 1 (ATA) antibodies, characterize
two different clinical SSc subsets. In limited cutaneous
scleroderma (lcSSc, 80% of SSc) the occurrence of ACA
is common [8] and Raynaud’s phenomena may precede
fibrotic skin by several years [1]. Diffuse cutaneous sys-
temic sclerosis (dcSSc) is less common, associated with
ATA, and an extensive skin involvement and pulmonary
fibrosis often parallel or may even precede Raynaud’s
phenomena.
In this study, we investigated the prevalence of
ischemic arterial events and measures of atherosclerosis
in patients with SSc and in controls from the general
population. Traditional cardiovascular risk factors were
tabulated. Since both atherosclerosis and cardiovascular
disease are known to be associated with systemic
inflammation, we also investigated the distribution of a
large set of inflammatory and endothelial biomarkers.
Methods
Patients and controls
All participants were >18 years old and recruited from the
adult population in Stockholm County (N = 1,534,272)
between August 2006 and December 2009. Prevalent cases
with SSc were identified at the three Rheumatology clinics
associated with general/university hospitals and from all
rheumatologists with private practice. All dermatologists,
gastroenterologists, specialists in respiratory medicine,
hand surgeons and general practitioners were contacted
twice and asked to inform us about their patients with
SSc. We identified 149 cases fulfilling the American Col-
lege of Rheumatology (ACR) criteria for SSc [9], which
corresponds to a prevalence of 97 adult SSc cases/million.
A total of 74% participated in the study. According to our
review of medical records, the remaining 26% did not dif-
fer from the included patients regarding age, disease dura-
tion or severe organ manifestations. Control subjects were
recruited from the same population through use of the
national registration number, which includes date of birth
and is coded for sex. The sex-matched person with the
birth date closest to the patient was contacted and asked
to participate. Some 65% of these ‘first choice’ controls
accepted to participate. When the ‘first choice’ declined,
the second-closest person was asked, until a control sub-
ject gave his/her consent. A diagnosis of SSc was the only
exclusion criteria. A total of 105 controls were included.
The local ethics committee of the Karolinska Univer-
sity Hospital approved the study and all participants
gave written informed consent.
Study protocol
All participants underwent a structured interview and a
physical examination by a rheumatologist (AN, LB).
The patients were classified as lcSSc or dcSSc using
the LeRoy classification [10]. Skin score was measured
with the modified Rodnan skin score [11] and disease
activity with the preliminary European Scleroderma
Study Group (EScSG) activity index [12]. The Medsger
scale of disease damage was used, with the exception
that the joint/tendon and muscular item was not per-
formed [13]. Organ involvement was defined as:
suspected pulmonary hypertension (sPH): tricuspidalis
V-max >2.9m/s on Doppler ultrasound. Pulmonary
fibrosis: signs of fibrosis on X-ray or high-resolution
computed tomography (HRCT). HRCT was performed
in 90% of the patients. Myositis: muscular weakness and
elevated creatine kinase and signs of inflammation on
magnetic resonance imaging (MRI), electromyography
(EMG) or muscular biopsy. Arthritis: swollen joints on
examination or arthritis documented in the journals.
Kidney involvement: a history of scleroderma renal crisis
or >1 on the Medsger scale for kidney damage [13].
Ischemic arterial events were defined as:
1. Ischemic heart disease (IHD): myocardial infarction
(confirmed by electrocardiography and a reversible rise
in plasma creatine kinase, muscle and brain fraction
(CK-MB) or troponin T) or angina pectoris (confirmed
by an exercise stress test).
2. Ischemic cerebrovascular disease (ICVD): cerebral
infarction (confirmed by computed tomography) or
transitory ischemic attacks (TIA, defined as transient
focal symptoms from the brain or retina with a maxi-
mum duration of 24 hours).
3. Ischemic peripheral vascular disease (IPVD): inter-
mittent claudication + ankle-brachial index (ABI) <0.9
or peripheral arterial thrombosis/embolus (confirmed by
angiogram or Doppler flow studies).
4. Any ischemic arterial event that includes 1 to 3
above
Measures of atherosclerosis
The left and right common carotid arteries and bifurca-
tion areas were scanned for presence of plaque and
images for IMT measurements were received using a
duplex scanner (Siemens Acuson Sequoia, Mountain
View, CA, USA) with a 7.0 MHz linear array transducer.
Scans were digitalized for offline analysis. The subject’s
head was tilted to get the picture of the common carotid
artery (CCA) just proximal to the bulb placed horizon-
tally across the screen. Pictures were frozen synchro-
nously with the R wave on the electrocardiogram. The
IMT was defined as the distance between the leading
edges of the luminal echo and the media/adventitia
echo [14]. The IMT was calculated as the intima-media
area divided by the measured length (10mm) on one
scan. Plaques were defined as a local increase in wall
thickness of >1 mm and 100% increase in wall thickness
Nordin et al. Arthritis Research & Therapy 2013, 15:R87
http://arthritis-research.com/content/15/4/R87
Page 2 of 12
compared to the adjacent wall. A technician recorded all
measurements and a single experienced reader (KJU)
interpreted the registrations without knowledge of
patient/control status or other test results.
To obtain the ABI, the patients were placed in a
supine position. The highest systolic pressure of the
tibialis posterior or dorsalis pedis for each foot were
divided by the highest brachial systolic pressure to
obtain an ankle-brachial pressure ratio.
Laboratory analyses
Antinuclear antibodies (ANA) were analyzed by immu-
nofluorescence (IFL) on sections of rat liver and HEp-2
cells (Immunoconcepts, Sacramento, CA, USA). Anticen-
tromere antibodies (ACA) and antitopoisomerase 1 antibo-
dies (ATA) were analyzed by the BioPlex 2200 ANA screen
system (Bio-Rad, Hercules, CA, USA). High-sensitivity
C-reactive protein (hsCRP), a-1 antitrypsin, orosomucoid
and fibrinogen were measured using BN ProSpec System
(Dade Behring, Deerfield, IL, USA). Intercellular adhesion
molecule 1(ICAM-1), vascular cell adhesion molecule
1(VCAM-1), interleukin 6 (IL-6) and vascular endothelial
growth factor (VEGF) were analyzed by sandwich ELISA
kits (DY720, DY206, DY137 and DY293B, R & D Systems,
Minneapolis, MN, USA). Cutoff values were 15 pg/mL for
ICAM-1, VCAM-1 and VEGF and 6 pg/mL for IL-6.
Cystatin C (reagent: 1014, Gentian, Moss, Norway) was
analyzed on an Architect Ci8200™ analyzer (Abbott,
Abbot Park, IL, USA). The total analytical imprecision of
the cystatin C method was 1.1% at 1.25 mg/L and 1.4% at
5.45 mg/L. The equation used for calculating glomerular
filtration rate (GFR) in mL/min/1.73 m2 from the cystatin
C results in mg/mL was y = 79.901x-1.4389[15].
von Willebrand factor (vWF) was measured by sand-
wich ELISA (Dako, Glostrup, Denmark) [16].
Statistical methods
Characteristics were summarized for all patients and con-
trols. Skewed continuous variables were log transformed
to obtain a normal distribution, if possible. Groups were
compared using ANOVA, Mann-Whitney U test and X2
test as needed. Odds ratio (OR) and 95% confidence inter-
vals (CI) were calculated from 2 × 2 contingency tables or
from nominal logistic regression models. For continuous
variables, we used standard least squares linear regression
to calculate standardized regression coefficients (b) and
P values. Variables were sorted into functional groups
(traditional risk factors, and so on. see Table 1). After age
adjustment, the variables within each group, which were
representative and most significantly, as determined by
lowest P value, associated with plaque occurrence were
entered into a multivariable-adjusted model. Due to lim-
ited number of plaques, we restricted the number of vari-
ables to six. Calculations were done using JMP software




At inclusion patients with SSc had lower body mass
index, lower diastolic blood pressure, but higher trigly-
cerides and biomarkers of systemic inflammation/
endothelial activation as compared to controls. Baseline
characteristics and comparisons between patients and
controls are given in Table 1.
Occurrence of ischemic arterial events and measures of
atherosclerosis
Ischemic arterial events were more common in patients
than in controls (Table 2), due to more prevalent IHD and
IPVD, while ICVD did not differ between groups (events
are tabulated in detail, see Additional file 1,Table 1). Of
participants with IHD, seven patients and three controls
were diagnosed with myocardial infarction. The remaining
IHD subjects had angina pectoris verified with an exercise
test, of these two patients and one control had undergone
an angiogram, all with normal cardiac vessels. Five patients
and one control had had multiple events.
The majority of the IPVD patients (78%) in our study
had severe macrovasculopathy requiring surgical interven-
tion. One SSc patient and the only control had IPVD
based on ABI <0.9 together with typical symptoms of clau-
dication (see Additional file 1, Table 1).
Plaque occurrence, IMT and ABI did not differ
between patients and controls (Table 2). Six patients and
two controls had an ABI below 0.9 and one patient and
one control had an ABI higher than 1.4.
Risk factors for ischemic arterial events
As expected, all ischemic arterial events were positively
associated with age. We therefore adjusted all further
calculations for age. All variables presented in Table 1
were investigated for associations with ischemic arterial
events. All variables, which after age adjustment
remained associated with at least one of the respective
cardiovascular outcomes (any event, IHD or IPVD), are
presented in Table 3. Age, kidney involvement, cystatin
C estimated (e)GFR were associated with any ischemic
arterial event and with IHD. ACA+ and skin score were
associated with any ischemic arterial event and IPVD.
Interestingly, patients with ATA had less total events
and less IHD. IHD was also associated with endothelial
biomarkers. Due to few events, we were not able to per-
form further multivariable calculations.
Risk factors for atherosclerosis
The investigated measures of atherosclerosis were all posi-
tively associated with age. Thus, all further calculations
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Table 1 Characteristics of systemic sclerosis patients and controls at inclusion.
Patients (n = 111) Controls (n = 105) P value
Age, years 61.8 ± 12.5 61.5 ± 12.3 ns
Gender female % (n) 81 (90) 86 (90) ns
Disease characteristics
Disease duration (years) 9.4 (5.6-17.4) - -
Diffuse cutaneous % (n)






Pulmonary fibrosis % (n) 46 (51) - -
Suspected pulmonary hypertension % (n) 15 (17) 0 -
Raynaud % (n) 95 (105) 11 (12) -
Digital ulcers ever % (n) 39 (43) 0 -
Calcinosis % (n) 27 (30) 0 -
Myositis % (n) 9 (10) 0 -
Arthritis % (n) 29 (32) 4 (4) -
Kidney involvement % (n) 7 (8) 0 -
Skin score 6 (3-10) 0 -
Disease activity 0.5 (0-2) - -
Disease severity 5 (3-6) - -
Autoantibodies
Anticentromere (ACA) % (n)
Antitopoisomerase 1 (ATA) % (n)







Traditional cardiovascular risk factors
Body mass index (kg/m2) 24.2 ± 3.80 26.0 ± 3.7 0.0005
Waist-hip ratio 0.83 ± 0.09 0.84 ± 0.08 ns
Ever smoked % (n)












































hsCRP (mg/l) 2.2 (1.0-4.3) 1.75 (0.76-3.2) 0.05
Orosomucoid (g/l) 0.86 ± 0.23 0.77 ± 0.17 0.0009
Alpha1antitrypsine (g/l) 1.5 (1.4-1.6) 1.4 (1.2-1.5) <0.0001










VCAM-1 (ng/l) 698 (546-807) 531 (431-719) <0.0001
ICAM-1 (ng/l) 376 (314-472) 330 (254-450) 0.002
VEGF (pg/ml) 182 (143-258) 156 (103-239) 0.009
vWF (IU/ml) 1.25 (0.90-1.70) 0.85 (0.58-1.36) <0.0001
Renal function
eGFR (mL/min/1.73 m2) 74 (50-116) 104 (89-126) 0.01
Distributions are given as % (n), median (interquartile range) or mean ± standard deviation. BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; hsCRP, high-sensitivity C reactive protein; VCAM-1, vascular cell adhesion molecule 1; ICAM-1, intercellular adhesion molecule 1; VEGF, vascular
endothelial growth factor; vWF, von Willebrand factor; eGFR, estimated glomerular filtration rate, based on cystatin C measurements.
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were age-adjusted. Each variable presented in Table 1 was
investigated for association with plaque occurrence,
IMT and ABI. All variables, which after age adjustment
remained associated with at least one of the respective
atherosclerosis outcomes (plaque, IMT or ABI), are pre-
sented in Table 4.
Plaque occurrence was associated with smoking,
higher blood pressure, impaired kidney function, high
levels of IL-6 and VCAM-1 and with ACA+.
As expected, we noted that IMT was strongly asso-
ciated with systolic blood pressure and with male gender.
ABI was associated with disease activity, waist-hip ratio
and smoking.
Several variables were associated with plaque occur-
rence and we included age and the variables with the
lowest P values in each ‘functional group’ in a multivari-
able-adjusted logistic regression. In this model only
ACA+ and high levels of IL-6 remained convincingly
associated with plaque occurrence, while the association
with diastolic blood pressure was of borderline signifi-
cance (Table 5).
Subgroup analysis of ACA+ SSc patients
Finally, due to the observed association between ACA+
and any ischemic arterial event and plaque occurrence, we
stratified by ACA status and compared the groups with
respect to all variables in Table 1. There were 34 ACA+
patients and 77 ACA-patients. In the ACA+ group disease
duration was longer (P = 0.04) and dcSSc, pulmonary
fibrosis, and ATA antibodies were less common (P < 0.05)
compared with the ACA-group. Of traditional risk factors,
waist-hip ratio, P-glucose and triglycerides levels were
lower in ACA+ patients (P ≤ 0.05). Levels of orosomucoid
and ICAM-1 were also lower in the ACA+ group
(P ≤ 0.05) (see Additional file 1, Table 2).
Occurrence of vascular events, measures of atherosclero-
sis and levels of endothelial markers in ACA+ and ACA-
patients (adjusted for age, sex and disease duration), and in
ACA+ patients and controls (adjusted for age and sex) are
demonstrated in Table 6, Figure 1, Figure 2 and Figure 3.
A higher total of ischemic arterial events, IPVD, and
more plaques were observed in ACA+ patients as com-
pared to both ACA-patients and controls.
Table 2 Ischemic arterial events and surrogate measures of atherosclerosis in systemic sclerosis patients versus controls.
Patients (n = 111) Controls (n = 105) Odds ratio (95% CI) P value
Any arterial event % (n) 18 (20) 7 (7) 3.1 (1.2-7.6) 0.01
IHD % (n) 12 (13) 4 (4) 3.3 (1.1-10.6) 0.03
ICVD % (n) 3 (4) 3 (3) 0.9 (0.2-4.7) ns
IPVD % (n) 8 (9) 1 (1) 9.2 (1.1-73.7) 0.02
Plaques % (n) 48 (52) 41 (43) 1.3 (0.7-2.3) ns
b-coefficient
IMT mm 0.68 ± 0.13 0.68 ± 0.13 -0.02 ns
ABI 1.13 (1.1-1.2) 1.12 (1.1-1.2) -0.08 ns
Any arterial event refers to any ischemic arterial event, including IHD, ICVD and IPVD. IHD, ischemic heart disease; ICVD, ischemic cerebrovascular disease; IPVD,
ischemic peripheral vascular disease; IMT, intima-media thickness; ABI, ankle-brachial index.
Table 3 Variables associated with ischemic arterial events in systemic sclerosis patients after age adjustment.
Any event (n = 20) IHD (n = 13) IPVD (n = 9)
Odds ratio (95% CI) P value Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age 1.10 (1.05-1.17) <0.0001 1.06 (1.01-1.13) 0.02 1.13 (1.05-1.26) 0.0005
Associations after adjustment for age
Kidney disease 8.8 (1.5-55.8) 0.01 6.6 (1.12-36.15) 0.04 ND 0.3
Skin score 1.13 (1.03-1.24) 0.008 1.07 (0.97-1.18) 0.1 1.16 (1.02-1.32) 0.02
Disease severity 1.29 (1.05-1.62) 0.02 1.11 (0.88-1.39) 0.4 1.15 (0.85-1.55) 0.3
ACA+ 3.61 (1.21-11.3) 0.02 1.9 (0.55-6.45) 0.2 6.8 (1.37-45.3) 0.02
ATA+ 0.18 (0.01-1.01) 0.05 0.00003 (0-0.6) 0.01 0.83 (0.04-5.67) 0.9
VCAM-1 5.30 (0.51-62.1) 0.2 27.3 (2.52-427. 4) 0.005 0.37 (0.02-5.46) 0.2
VEGF 0.68 (0.24-1.84) 0.4 0.29 (0.09-0.93) 0.03 0.52 (0.12-2.33) 0.4
eGFR 0.26 (0.10-0.62) 0.003 0.32 (0.12-0.81) 0.02 0.57 (0.15-3.65) 0.5
IHD, ischemic heart disease; IPVD, ischemic peripheral vascular disease; CI, confidence interval; ACA, anticentromere antibody; +, positivity; ATA,
antitopoisomerase 1 antibody; VCAM-1, vascular cell adhesion molecule 1; VEGF, vascular endothelial growth factor; eGFR, estimated glomerular filtration rate,
based on cystatin C measurements.
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Discussion
The first major finding in this population-based study is
that ischemic arterial events, specifically IHD and IPVD,
are more common in patients with SSc, while ICVD and
measures of atherosclerosis did not differ on a group
level as compared to population controls. Second, the
ACA+ SSc subgroup was more affected with ischemic
arterial events and with carotid plaques in comparison
both to other SSc patients and to controls.
The observed high prevalence of IPVD in patients
with SSc highlights an important clinical problem
recently also reported by Man et al. [17]. Youssef et al.
[18] found an even higher prevalence of IPVD in
females with lcSSc compared with controls (58%
vs.10%). More claudication, as a sign of IPVD, was also
reported in SSc patients by Veale and collaborators [19].
Despite the higher prevalence of IPVD, SSc patients
did not, as a group, have lower ABI than controls. This
is in line with three previous studies [20-22], but con-
trasts with Ho et al. [23]. In our study, ACA+ patients
had more IPVD compared to both ACA-patients and
controls and there was also a trend toward lower ABI in
the ACA+ group. Wan et al. examined ABI in 119 SSc
patients and found no difference between patients with
lcSSc and dcSSc, but interestingly ACA+ seemed to pre-
vail among patients with symptomatic ischemic disease
[24]. Previous studies have identified ACA+ as a predic-
tor for severe digital loss [25,26]. Thus, in addition to
microvascular disease, the large arteries of the extremi-
ties seem to contribute significantly to the severe distal
ischemic damage seen in many SSc patients, especially
in the ACA+ subgroup.
We report a three-fold increased occurrence of IHD in
SSc patients and even higher figures in the ACA+ sub-
group. This is in line with the recently reported inci-
dence of myocardial infarction [17] and self-reported
IHD [27], both of which were two-fold enhanced in SSc
patients versus the general population. Older autopsy
studies described that myocardial infarctions were
Table 4 Variables associated with measures of atherosclerosis in systemic sclerosis patients after age adjustment.
Plaques (n = 52) IMT ABI
Odds ratio
(95% CI)
P value b-coefficient P value b-coefficient P value
Age 1.09 (1.05-1.14) <0.0001 0.66 <0.0001 -0.20 0.03
Associations after adjustment for age
Gender female 0.39 (0.12-1.18) 0.1 -0.19 0.0001 -0.12 0.2
ACA+ 2.9 (1.2-7.5) 0.02 -0.01 0.9 -0.14 0.2
Digital ulcers 2.6 (1.1-6.6) 0.03 0.10 0.2 -0.09 0.4
Kidney disease 11.5 (1.7-232) 0.03 -0.05 0.5 0.05 0.6
Disease activity 1.6 (1.04-2.5) 0.03 0.10 0.2 -0.34 0.0004
Disease severity 1.3 (1.1-1.5) 0.005 0.12 0.1 0.13 0.2
Waist-hip ratio 2.6 (0.01-645) 0.7 0.09 0.2 0.19 0.04
Ever smoked 2.5 (1.05-6.7) 0.04 0.10 0.2 0.24 0.01
Systolic BP 1.0 (1.0-1.1) 0.02 0.28 0.0008 -0.06 0.6
Diastolic BP 1.1 (1.0-1.1) 0.008 0.13 0.1 -0.02 0.9
Interleukin-6 3.5 (1.5-9.3) 0.003 0.12 0.1 -0.13 0.2
VCAM-1 9.4 (1.8-58.3) 0.008 -0.05 0.5 0.03 0.8
ICAM-1 0.32 (0.05-1.98) 0.2 0.16 0.04 -0.12 0.2
eGFR 0.4 (0.2-0.99) 0.04 0.11 0.2 -0.04 0.7
IMT, intima-media thickness; ABI, ankle-brachial index; CI, confidence interval; ACA, anticentromere antibodies; +, positivity; BP, blood pressure; VCAM-1, vascular
cell adhesion molecule 1; ICAM-1, intercellular adhesion molecule 1; eGFR, estimated glomerular filtration rate, based on cystatin C measurements.








Age 1.1 (1.03-1.16) 0.003
Disease characteristics
ACA+ 4.0 (1.26-14.1) 0.02
Traditional risk factors
Diastolic blood pressure (mmHg) 1.1 (1.01-1.11) 0.04
Inflammatory biomarkers
IL-6 (pg/ml) 3.8 (1.3-13.3) 0.01
Endothelial biomarkers
VCAM-1 (ng/ml) 1.5 (0.15-14.7) 0.7
Kidney function test
eGFR (mL/min/1.73 m2) 0.3 (0.04-1.07) 0.07
CI, confidence interval; ACA, anticentromere antibodies; +, positivity; IL,
interleukin; VCAM-1, vascular cell adhesion molecule 1; eGFR, estimated
glomerular filtration rate, based on cystatin C measurements.
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Table 6 Ischemic arterial events and surrogate measures of atherosclerosis in ACA+ patients versus ACA-patients and
controls.









P value** Odds ratio*
(95% CI)
P value*
Any arterial event % (n) 32 (11) 11 (9) 7 (7) 5.1 (1.57-18.6) 0.01 8.5 (2.6-31.7) 0.0003
IHD % (n) 18 (6) 9 (7) 4 (4) 2.6 (0.7-10.0) 0.2 4.8 (1.2-20.7) 0.02
ICVD % (n) 6 (2) 3 (2) 3 (3) 4.0 (0.4-49.0) 0.2 2.0 (0.2-13.9) 0.6
IPVD % (n) 18 (6) 4 (3) 1 (1) 9.1 (1.6-79.1) 0.01 70.1 (6.5-2524) <0.0001
Plaque % (n) 65 (22) 39 (30) 41 (43) 3.1(1.2-8.5) 0.02 2.8 (1.1-7.6) 0.04
b-coefficient b-coefficient
IMT mm 0.69 ± 0.13 0.68 ± 0.13 0.68 ± 0.13 0.03 0.7 0.01 0.6
ABI 1.1(1.03-1.2) 1.1 (1.17-1.2) 1.1 (1.07-1.2) -0.12 0.08 -0.14 0.07
Distributions are given as %, median (interquartile range) or mean ± standard deviation. **adjusted for age, sex and disease duration; *adjusted for age and sex.
ACA, anticentromere antibodies; +, positivity; -, negativity; CI, confidence interval; IHD, ischemic heart disease; ICVD, ischemic cerebrovascular disease; IPVD,























Figure 1 Ischemic arterial events in ACA+ and ACA-patients and in controls. Bar graph describing the frequency of ischemic arterial events
in systemic sclerosis patients with (+) or without (-) anticentromere antibodies (ACA) and in comparable controls. Ischemic arterial events are
defined as: Ischemic heart disease (IHD): myocardial infarction (confirmed by electrocardiography and a reversible rise in plasma creatine kinase,
muscle and brain fraction (CK-MB) or troponin T) or angina pectoris (confirmed by exercise stress test). Ischemic cerebrovascular disease (ICVD):
cerebral infarction (confirmed by computed tomography) or transitory ischemic attacks (TIA, defined as transient focal symptoms from the brain
or retina with a maximum duration of 24 hours). Ischemic peripheral vascular disease (IPVD): intermittent claudication + ABI <0.9 or peripheral
arterial thrombosis/embolus (confirmed by angiogram or Doppler flow studies). P values between ACA+ versus ACA- are adjusted for age,
gender and disease duration and P values for ACA+ versus controls are adjusted for age and gender.
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common in SSc patients, despite normal coronary
arteries [28,29]. Akram et al. evaluated 179 angiograms
from SSc patients but did not find an increased preva-
lence of coronary atherosclerosis [30] and normal angio-
grams were more common than expected among 11 SSc
patients with myocardial infarction [31]. These studies
suggest that vasospasm rather than atherosclerosis is a
major pathogenic mechanism behind SSc-related heart
disease. On the other hand, MRI studies have found that
calcification of cardiac vessels are common in SSc [32].
The inconsistent results of previous work may partly be


























Figure 2 Measures of atherosclerosis in ACA+ and ACA-patients and in controls. Outlier box plots of (A) intima-media thickness and
(B) ankle-brachial index in systemic sclerosis patients with (+) or without (-) anticentromere antibodies (ACA) and in comparable controls. The
median, interquartile range (IQR) and the lowest value still within 1.5 IQR of the lower quartile, and the highest value still within 1.5 IQR of the
upper quartile are represented by the box and whiskers. The dots represent the individual samples. (C) is a bar graph describing the frequency
of plaques (%) in ACA+, ACA-patients and controls. P values between ACA+ versus ACA- are adjusted for age, gender and disease duration and
P values for ACA+ versus controls are adjusted for age and gender.
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occurrence is selectively enhanced in the ACA+ sub-
group of SSc patients.
In our study, impaired kidney function was highly asso-
ciated with IHD, a finding that is supported by Derk et al.,
who reported that the majority of SSc patients with IHD
had renal failure [30].
Cerebrovascular disease was, in accordance with Yous-
sef et al., equally common in SSc patients and controls
[18]. However, recently Man et al. reported enhanced
incidence of stroke in a large epidemiological study [17].
On a group level, there was no difference between
patients and controls concerning atherosclerosis, mea-
sured as plaques occurrence, IMT or ABI. Our study
population was fairly old and the plaque frequency was
high in both patients and controls. Previous studies are
smaller and the majority measured only IMT. Some
Figure 3 Markers of endothelial activation in ACA+ and ACA-patients and in controls. Outlier box plots of (A) vascular cell adhesion
molecule 1 (VCAM-1), (B) intercellular adhesion molecule 1 (ICAM-1), (C) von Willebrand factor (vWf) and (D) vascular endothelial growth factor
(VEGF) in systemic sclerosis patients with (+) or without (-) anticentromere antibodies (ACA) and in comparable controls. The median,
interquartile range (IQR) and the lowest value still within 1.5 IQR of the lower quartile, and the highest value still within 1.5 IQR of the upper
quartile are represented by the box and whiskers. The dots represent the individual samples. P values between ACA+ versus ACA- are adjusted
for age, gender and disease duration and P values for ACA+ versus controls are adjusted for age and gender.
Nordin et al. Arthritis Research & Therapy 2013, 15:R87
http://arthritis-research.com/content/15/4/R87
Page 9 of 12
report, in agreement with us, similar IMT in patients and
controls [5,33-37], others found thicker IMT in SSc
patients [20,38-40]. Only three studies examined the fre-
quency of plaques, but their definitions of plaque differ
[20,23,41]. We had no exclusion criteria, while some stu-
dies excluded SSc patients with manifest cardiovascular
disease (CVD) [4,20,35,36]. Furthermore, the selection of
comparators is important. The healthy controls in pre-
vious studies are likely to have less atherosclerosis than
our population-based controls. Methods, definition and
selection procedures of both patients and controls are
likely to contribute to the heterogeneity of previous stu-
dies, reviewed in a recent meta-analysis [7].
Generally, levels of endothelial and inflammatory bio-
markers were higher in patients compared to controls,
demonstrating that SSc is a low-grade inflammatory dis-
ease. Of investigated inflammatory biomarkers, IL-6
remained independently associated with plaques. For SSc
this is a new observation but IL-6 has been identified as a
risk factor for subclinical coronary atherosclerosis in RA
[42], and it has also been linked to poor prognosis in
patients with IHD from the general population [43].
VCAM-1 was associated with both IHD and plaques,
though the latter association did not remain in multivari-
able analysis. In a previous study VCAM was associated
with arterial stiffness in patients with SSc [44]. We
reported recently in a prospective study that VCAM-1
levels predicted cardiovascular mortality in SLE [45]. The
present observation adds further support for a pivotal role
of the endothelium in autoimmune vascular disease.
Plaques were more common in ACA+ SSc patients,
compared both to ACA-patients and controls. This dif-
ference remained after adjustment for disease duration,
gender and age.
It is of note that, despite the enhanced occurrence of
ischemic arterial events and plaques, several traditional
CVD risk factors (waist-hip ratio, plasma glucose and tri-
glycerides) had a less ‘atherogenic’ profile in the ACA+ as
compared to the ACA-patients. Another important obser-
vation is that ischemic events were rare in the ATA+
group. These patients are part of the ACA-group, which
consists of patients with different autoantibody profiles. In
previous studies, ACA+ patients had a different disease
presentation with more localized skin involvement, calci-
nosis [46], digital loss [26] and also a different genetic
background [47]. Cheng et al. previously noted that the
carotid wall of patients with SSc was stiffer than that of
controls, and in subgroup analysis stiffness was more pro-
nounced in dcSSc than in lcSSc [33]. Together these
results imply that the antibody profiles and associated dis-
ease subsets contribute to vascular vulnerability in SSc.
To date this is the largest epidemiologically based study
investigating both ischemic macrovascular disease and
atherosclerosis in patients with SSc and in comparable
population-based controls. Nevertheless, we are under-
powered for more detailed subgroup analysis and for
multivariable analysis of events. The cross-sectional
design is a weakness restricting our investigation to survi-
vors of vascular events. Case definitions in the national
registries are based on ICD codes and differ from the
definitions used in this study. We were thus restricted to
compare event rates to our own controls, and could not
reliably use the general population/national registries.
Conclusions
We report increased prevalence of ischemic arterial
events, affecting preferentially the heart and peripheral
arteries in SSc patients, especially in ACA+ patients,
where also atherosclerosis was enhanced. Our results
demonstrate the importance to perform detailed clinical
descriptive studies, including subgroup analysis of estab-
lished diagnostic entities. The importance to investigate
both the macro- and microvasculature in SSc is under-
scored. In particular, ACA+ patients should be moni-
tored closely and modifiable cardiovascular risk factors
treated at an early stage to avoid ischemic complications
such as amputations and myocardial infarctions.
Additional material
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of ACA+ versus ACA-SSc patients.
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